Abstract
Background: In May 2018, the monovalent MenC-TT conjugate vaccine given at 14 months of age within the National Immunization Programme in the Netherlands was replaced by a 4-valent MenACWY-TT conjugate vaccine. Methods: Results from a questionnaire about local reactions and systemic events within 4 days after vaccination were compared with data from a comparable tolerability study of a monovalent MenC-TT vaccine. Results: The response rate was 5.5% (1157/20966 questionnaires). Any local reaction was reported for 3.7% of the toddlers, with the highest percentage found for local redness at the injection site (2.9%). Any systemic event was reported for 32.4% of the toddlers, with listlessness (22.4%) most often reported. Fever was the only symptom more frequently reported after MenACWY-TT vaccination compared with MenC-TT vaccination (adj OR 1.61; 95% CI 1.29-2.01).Conclusions: the 4-valent MenACWY-TT vaccine showed to be a little more reactogenic compared with to the monovalent MenC-TT vaccine, with a higher risk of fever within 4 days after vaccination. For the other factors no increased risks were found. Overall, this study shows that MenACWY-TT vaccination is well tolerated in toddlers.
Economic Impact of Pneumococcal Protein-D Conjugate Vaccine (PHiD-CV) on the Malaysian National Immunization Programme
